This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

4 Plays Under $10 on the Rise

Protalix BioTherapeutics (PLX)

This is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on the company's proprietary ProCellExtm protein. This stock closed up 8.8% to $5.31 in recent trading.

Today's Range: $4.97-$5.56

52-Week Range: $4.71-$7.70

Volume: 744,000

Three-Month Average Volume: 145,775

Shares of PLX exploded higher after the Globes reported the company is close to signing an agreement for selling its Gaucher's disease treatment to the government of Brazil. The deal is reportedly worth hundreds of millions of dollars.

From a technical perspective, PLX ripped higher today back above its 50-day moving average of $5.05 with monster upside volume. This move also pushed PLX into breakout territory, since the stock took out some near-term overhead resistance levels at $5.19 to $5.40. Shares of PLX are now trending within range of triggering another major breakout trade. That trade will hit once PLX manages to take out some more overhead resistance levels at $5.80 to $6.07 with high volume.

Traders should now look for long-biased trades in PLX as long as it's trending above $5.40, and then once it sustains a move or close above those breakout levels with volume that hits near or above 154,775 shares. If that breakout triggers soon, then look for PLX to re-test or possibly take out its next major overhead resistance levels at $6.80 to $7. Any high-volume move above $7 would then put $7.70 into focus for PLX.

Insmed (INSM)

This is a development-stage biopharmaceutical company. The company develops inhaled treatments for serious lung infections. This stock closed up 7.5% to $7.51 in recent trading.

Today's Range: $6.90-$7.70

52-Week Range: $2.64-$7.17

Volume: 822,000

Three-Month Average Volume: 147,395

Shares of INSM trended up today after the company said its CLEAR-108 phase 3 clinical study of Arikace in Cystic Fibrosis patients with pseudomonas lung infections has completed target enrollment.

From a technical perspective, INSM trended up strongly today with monster upside volume. This move has now pushed INSM into breakout territory, since the stock cleared some near-term overhead resistance levels at $7.14 to $7.17.

2 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,156.85 +24.88 0.15%
S&P 500 2,001.57 +2.59 0.13%
NASDAQ 4,562.1890 +9.43 0.21%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs